Kalvista Pharmaceuticals Inc expected to post a loss of 79 cents a share - Earnings Preview

Kalvista Pharmaceuticals

04/12/2023 13:41

* Kalvista Pharmaceuticals Inc  KALV.OQ   KALV.O  is
expected
to show no change in quarterly revenue when it reports  results 
for the period ending July 31 2023
    * 
    * ​LSEG's mean analyst estimate for Kalvista Pharmaceuticals
Inc
is for a loss of 79 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kalvista
Pharmaceuticals Inc is $20.00​, above​ its last closing price
of $8.82. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jul. 31 2023  -0.84       -0.86      -0.74     Beat    13.8
 Apr. 30 2023  -0.83       -0.94      -0.77     Beat    17.9
 Jan. 31 2023  -0.92       -0.98      -0.75     Beat    23.9​
 Oct. 31 2022  -1.03       -1.06      -0.90     Beat    14.8
 ​​Jul.        -1.03       -1.04      -0.94     Beat    9.6
 31 2022                                                
 Apr. 30 2022  -1.07       -1.09      -0.98     Beat    9.8​
 Jan. 31 2022  -0.90       -0.93      -0.92     Beat    0.6
 Oct. 31 2021  -0.76       -0.79      -0.80     Missed  -1.1
 This summary was machine generated December 4 at 13:41 GMT.  All
figures in US dollars unless otherwise stated